Literature DB >> 12850789

Artificial T-cell receptors.

M Pule1, H Finney, A Lawson.   

Abstract

Artificial T-cell receptors are generated by joining an Ag-recognizing domain (ectodomain) to the transmembrane and intracellular portion of a signaling molecule (endodomain). The ectodomain is most often derived from Ab variable chains, but may also be generated from T-cell receptor variable chains, as well as from other molecules. Various alternative ectodomain designs exist, with some comparative studies suggesting optimal forms. The endodomain most often used is the intracellular portion of CD-zeta. Although signaling by CD-zeta leads to IFN-n release and cell killing, it fails to transmit a full activation signal. Recently, unions of different signaling molecule segments have facilitated transmission of more potent signals, stimulating T-cell proliferation and overcoming this major limitation. Artificial T-cell receptors allow grafting of nearly any specificity to T cells. This allows generation of large numbers of specific T cells, without laborious selection and expansion procedures. Efficacy against tumors has been demonstrated in animal models. Phase I and II studies of T-cells transduced with artificial T-cell receptors as therapy for HIV infection have been performed. This rapidly advancing technology will make new strategies of adoptive immunotherapy possible.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12850789     DOI: 10.1080/14653240310001488

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  20 in total

1.  An inducible caspase 9 safety switch for T-cell therapy.

Authors:  Karin C Straathof; Martin A Pulè; Patricia Yotnda; Gianpietro Dotti; Elio F Vanin; Malcolm K Brenner; Helen E Heslop; David M Spencer; Cliona M Rooney
Journal:  Blood       Date:  2005-02-22       Impact factor: 22.113

2.  Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells.

Authors:  Virna Marin; Elisabetta Cribioli; Brian Philip; Sarah Tettamanti; Irene Pizzitola; Andrea Biondi; Ettore Biagi; Martin Pule
Journal:  Hum Gene Ther Methods       Date:  2012-12       Impact factor: 2.396

Review 3.  Gene therapy: charting a future course--summary of a National Institutes of Health Workshop, April 12, 2013.

Authors:  Marina O'Reilly; Howard J Federoff; Yuman Fong; Donald B Kohn; Amy P Patterson; Nabil Ahmed; Aravind Asokan; Shannon E Boye; Ronald G Crystal; Satiro De Oliveira; Linda Gargiulo; Scott Q Harper; Yasuhiro Ikeda; Robert Jambou; Maureen Montgomery; Lawrence Prograis; Eugene Rosenthal; Daniel H Sterman; Luk H Vandenberghe; Laurie Zoloth; Mehrdad Abedi; Jennifer Adair; Prasad S Adusumilli; William F Goins; Jhanelle Gray; Paul Monahan; Leslie Popplewell; Miguel Sena-Esteves; Bakhos Tannous; Thomas Weber; William Wierda; Rashmi Gopal-Srivastava; Cheryl L McDonald; Daniel Rosenblum; Jacqueline Corrigan-Curay
Journal:  Hum Gene Ther       Date:  2014-06       Impact factor: 5.695

4.  Print Me an Organ? Ethical and Regulatory Issues Emerging from 3D Bioprinting in Medicine.

Authors:  Frederic Gilbert; Cathal D O'Connell; Tajanka Mladenovska; Susan Dodds
Journal:  Sci Eng Ethics       Date:  2017-02-09       Impact factor: 3.525

Review 5.  Immunotherapy as a Potential Treatment for Chordoma: a Review.

Authors:  Shalin S Patel; Joseph H Schwab
Journal:  Curr Oncol Rep       Date:  2016-09       Impact factor: 5.075

6.  T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells.

Authors:  Juan Vera; Barbara Savoldo; Stephane Vigouroux; Ettore Biagi; Martin Pule; Claudia Rossig; Jessie Wu; Helen E Heslop; Cliona M Rooney; Malcolm K Brenner; Gianpietro Dotti
Journal:  Blood       Date:  2006-08-22       Impact factor: 22.113

7.  Intranasal delivery of central nervous system-retargeted human mesenchymal stromal cells prolongs treatment efficacy of experimental autoimmune encephalomyelitis.

Authors:  Moa Fransson; Elena Piras; Hao Wang; Joachim Burman; Ida Duprez; Robert A Harris; Katarina LeBlanc; Peetra U Magnusson; Eva Brittebo; Angelica S I Loskog
Journal:  Immunology       Date:  2014-07       Impact factor: 7.397

8.  Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression.

Authors:  Nabil Ahmed; Vita S Salsman; Eric Yvon; Chrystal U Louis; Laszlo Perlaky; Winfried S Wels; Meghan K Dishop; Eugenie E Kleinerman; Martin Pule; Cliona M Rooney; Helen E Heslop; Stephen Gottschalk
Journal:  Mol Ther       Date:  2009-06-16       Impact factor: 11.454

Review 9.  Immunotherapy of human cancers using gene modified T lymphocytes.

Authors:  Juan F Vera; Malcolm K Brenner; Gianpietro Dotti
Journal:  Curr Gene Ther       Date:  2009-10       Impact factor: 4.391

10.  Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells.

Authors:  Eric Yvon; Michele Del Vecchio; Barbara Savoldo; Valentina Hoyos; Aurélie Dutour; Andrea Anichini; Gianpietro Dotti; Malcolm K Brenner
Journal:  Clin Cancer Res       Date:  2009-09-08       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.